Borregaard ASA (BRGAY) Discusses Outlook for BioSolutions and BioMaterials, Market Trends, and Volume Expectations Transcript

Key takeaway: Borregaard expects BioSolutions sales volume of ~340,000 tonnes for the full year and Q1 volume of ~80,000 tonnes (vs 81,000 in Q1 2025, roughly flat). Management cites continued growth in the agriculture segment and improvements in biovanillin, but notes EBITDA for 2025 (outside Q1) was not materially stronger than 2024. Guidance is volume-driven and likely to be neutral-to-modestly supportive for near-term earnings, with limited market-moving implications.

Analysis

Stable Q1 volumes and guidance centered on agriculture and biovanillin imply the earnings lever for Borregaard shifts from volume surprise to mix and unit margin improvement; every 1% realized margin uplift on BioSolutions translates to a disproportionate EBITDA gain because fixed-cost absorption in a biorefinery is high and SG&A is relatively fixed. Expect margin sensitivity to feedstock (wood/softwood) pulp prices and power costs — a 10% move in Norwegian industrial power prices or a comparable swing in pulp spot can move company-level EBITDA by mid-single-digit millions within a quarter.

Second-order winners include specialty formulation buyers (animal feed and crop inputs) that gain more stable, possibly cheaper bio-based intermediates if Borregaard scales agriculture volumes; conversely commodity pulp players will feel pressure if Borregaard reallocates feedstock toward higher-margin specialties, tightening low-grade pulp supply and pushing pulp spreads wider. Logistics and seasonality risk matter: agriculture demand concentrates in planting seasons, so working capital and inventory cycles will amplify P&L volatility in Q2–Q3 even if full-year volumes are stable.

Key short-term catalysts to monitor are: Norwegian power forward curves for next 6–12 months, pulp spot and contract prices in Europe, and biovanillin order cadence (lumpy contracts can swing quarterly EBITDA). Tail risks include a rapid deterioration in agricultural demand from macro recession or a sharp commodity deflation that would erase any realized premium on specialty products; such reversals would materialize within 1–3 quarters and compress margins quickly.

From a medium-term perspective (6–18 months) watch management’s capital allocation—incremental investments to raise specialty capacity will be high-IRR only if the company secures multi-year offtake contracts; absent that, capacity additions could dilute returns and increase cyclicality.

Key Decisions for Investors

• Long BRGAY (equity/OTC) — enter 6–12 month horizon. Rationale: buy exposure to margin re-rating if agriculture mix and biovanillin scale; target asymmetric payoff if energy and pulp prices normalize higher. Risk/reward: set stop at 12–15% downside; target 30–50% upside if EBITDA margin improves 200–300bps.
• Pair trade: Long BRGAY / Short UPM (UPMJF) or Sappi (SSPDF) — 3–9 month horizon. Rationale: long specialty-biochemical exposure vs commodity pulp cyclicality. Position size: 1:1 notional; unwind if Nordic power forwards rally >20% (cuts into Borregaard margin). Expect 20–40% relative outperformance if specialty mix premium materializes.
• Options hedge: Buy BRGAY 9–12 month calls or call spread (OTC liquidity permitting) sized to 50% of equity exposure. Rationale: caps downside cost while retaining upside from cyclically improving specialty prices. Risk/reward: premium limited; break-even requires ~15–20% move in implied equity value.
• Event watch & tactical short: Initiate a small tactical short in late Q2 if inventories rise ahead of harvest/planting (indicator from company updates or Baltic port flows). Rationale: lumpy order flow can trigger an earnings miss; time horizon 30–90 days. Risk: cut quickly on any guidance reiteration or buyback signals.